Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine in OAB patients with sub-optimal response to tolterodine
NCT01302054Phase 4Completed
- Sponsor
- Pfizer
- Start
- May 2011
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Fesoterodine with Placebo (2 arms). Primary endpoints: Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 and Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12. Started May 2011; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01302054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302054.